Superlymph cytokine-peptide complex explored as antibiotic alternative for chronic cystitis exacerbations

Treatment for cystitis heavily relies on antibiotics, which contributes to rising antimicrobial resistance among uropathogens and increases adverse events like dysbiosis. There is a critical need for non-antibiotic alternatives to manage acute exacerbations of chronic cystitis, particularly for patients with contraindications or intolerance to traditional antibacterial drugs. This study explores a novel cytokine and antimicrobial peptide complex (Superlymph) as a potential monotherapy to address this gap.

This pilot open-label prospective non-comparative study enrolled 30 female patients (aged 20 to 49 years) with chronic cystitis during exacerbation. All patients presented with acute symptoms, including frequency and painful urination (30/100%), dysuria (22/73.3%), and urethral bleeding (7/23%), with disease duration averaging 18.8+/-2.4 hours. Patients refused antibiotics due to reasons such as planned pregnancy, allergies, or prior antibiotic-associated dysbiosis. Participants received Superlymph suppositories rectally in a two-stage regimen: an intensive phase of 25 IU daily for 20 days, followed by a continuation phase of 10 IU for 10 days. The study aimed to evaluate the efficiency, safety, and tolerability of this monotherapy.

The provided abstract is truncated and does not include the results section. Therefore, specific findings regarding the efficiency, safety, or tolerability of Superlymph suppositories in patients with chronic cystitis during exacerbation cannot be reported. The abstract concludes abruptly before detailing any outcomes, statistical data, or patient response rates. No specific percentages, p-values, or fold-changes are available to quote from the abstract.